Biosimilar Opinions in October 2026: Ranibizumab and Filgrastim Enter the Pipeline to Market

Two biosimilars received positive CHMP opinions in October 2026: Fovlussea (ranibizumab) for wet age-related macular degeneration and other visual impairments, and Neuzafy (filgrastim) for neutropenia. For market access teams, the work begins at the opinion.

What was recommended

EMA’s highlights list both products among six new medicines recommended. The Commission decision normally follows within 67 days, after which the products can be marketed in the EU subject to national steps.

Two very different settings

  • Ophthalmology. Intravitreal products involve hospital pharmacy purchasing and specialist prescribing, so tendering and hospital formularies are important routes.
  • Supportive oncology care. Filgrastim is used across many treatment settings, where price competition and prescribing habits are decisive.

Greek market access considerations

Biosimilar uptake depends on pricing rules, reimbursement listing, hospital procurement and prescriber confidence. Evidence on equivalence is established through the EU regulatory assessment, and EMA and the HMA have published statements supporting interchangeability of authorised biosimilars, but communication to clinicians remains important.

Timing

Launch readiness requires submission of national pricing and reimbursement files, packaging and labelling in Greek, pharmacovigilance set-up and distribution agreements. Doing these in parallel with the Commission decision shortens the time to patient access.

How PQRA helps

PQRA supports biosimilar developers and distributors with national pricing and reimbursement submissions, labelling and artwork, pharmacovigilance set-up and launch readiness in Greece.

Contact PQRA to discuss your situation

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *